Effect of hypertonic sodium chloride hydroxyethyl starch 40 on ET, TXB2, 6-keto-PGF1α, and ANP of preeclampsia in caesarean section

Abstract

Objective: Preeclampsia is a unique disease of pregnancy. Delivery via caesarean section is the most important way of terminating thepregnancy and treating preeclampsia. Perioperative fluid therapy is performed to maintain the circulatory volume and reduce tissue edema.This study evaluated the effects of hypertonic sodium chloride hydroxyethyl starch 40 (HSH40) as perioperative fluid therapy forpreeclampsia patients. Materials and Methods: Forty preeclamptic women were randomly divided into two groups: the Ringer’s solutiongroup and the HSH40 group. Their ECG, HR, MAP, and SPO2 were monitored. Their MVP and HR were recorded at five, eight, and tenminutes after anesthesia induction and at the end of the caesarean section. The corresponding volume of infusion, blood loss, and urineoutput during the operation were also recorded. Venous samples were collected before HSH40 infusion and 30 min after infusion to measurethe plasma concentrations of ET, TXB2, 6-keto-PGF1α, and ANP via a radioimmunoassay. Results: HSH40 infusion significantly decreasedthe plasma ET levels (p Conclusion: Low-dose HSH40 lowers the plasma levels of vasoconstrictor substances (ET and TXB2) andincreases the levels of vasodilator substances (6-keto-PGF1α and ANP) during preeclampsia. It effectively maintains and stabilizes thecirculating blood volume, increasing renal blood flow, which improves renal function and increases urine output.